Why the study?
Lipid-lowering in patients with CAD reduces cardiovascular events, but factors related to hypercholesterolemia management in established CAD needed evaluation.
What factors are associated with the use of lipid-lowering drugs and achievement of LDL cholesterol goals in patients with established CAD?
Observational
What factors are associated with the use of lipid-lowering drugs and achievement of LDL cholesterol goals in patients with established CAD?
Odds Ratio: 5.88 (95% CI 3.05–11.34)
Health-system-related factors primarily drive lipid-lowering drug utilization, whereas patient-related factors determine the successful achievement of LDL cholesterol goals following hospitalization for CAD.
Lipid-lowering in patients with coronary artery disease (CAD) is related to a lower risk of cardiovascular events. We evaluated factors related to the management of hypercholesterolemia in patients with established CAD. Patients were interviewed 6-18 months after hospitalization for an acute coronary syndrome (ACS) or a myocardial revascularization procedure. Statins were prescribed at discharge to 94.4% of patients, while 68.1% of the patients hospitalized for an ACS were prescribed a high-dose statin. Hospitalization in a teaching hospital, percutaneous coronary intervention, cholesterol measurement during hospitalization and the male sex were related to prescription of statins at discharge. The intensity of lipid-lowering therapy in the post-discharge period increased in 17.3%, decreased in 11.7%, and did not change in 71.0% of the patients. The prescription of a lipid-lowering drug (LLD) at discharge (odds ratio 5.88 [95% confidence intervals 3.05-11.34]) and a consultation with a cardiologist (2.48 [1.51-4.08]) were related to the use of LLDs, while age (1.32 [1.10-1.59] per 10 years), loneliness (0.42 [0.19-0.94]), professional activity (1.56 [1.13-2.16]), and diabetes (1.66 [1.27-2.16]) were related to achieving an LDL cholesterol goal 6-18 months after discharge. In conclusion, health-system-related factors are associated with the LLD utilization, whereas mainly patient-related factors are related to the control of hypercholesterolemia following hospitalization for CAD.
No takes yet. Share an insight, caveat, or question.
Jankowski et al. (2021) conducted an observational in Coronary Artery Disease. Prescription of a lipid-lowering drug at discharge was evaluated on Use of lipid-lowering drugs 6-18 months after discharge (OR 5.88, 95% CI 3.05-11.34).
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: